Evidence map›Paper›PMID 34790962›Full record

ArticleDiscover oncology2021

Endothelial cell-specific reduction of heparan sulfate suppresses glioma growth in mice.

Takamasa Kinoshita, Hiroyuki Tomita, Hideshi Okada, Ayumi Niwa, Fuminori Hyodo, Tomohiro Kanayama, Mikiko Matsuo, Yuko Imaizumi, Takahiro Kuroda, Yuichiro Hatano and 11 more

Open access · goldAbstract read
In one paragraph

Article in Discover oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 5 institutions in 2 countries.

Takamasa KinoshitaDepartment of Tumor Pathology, Gifu University Graduate School of Medicine, Gifu, 501-1194 Japan.
Hiroyuki TomitaDepartment of Tumor Pathology, Gifu University Graduate School of Medicine, Gifu, 501-1194 Japan.ORCID 0000-0002-3291-0274
Hideshi OkadaDepartment of Emergency and Disaster Medicine, Gifu University Graduate School of Medicine, Gifu, 501-1194 Japan.ORCID 0000-0002-7775-4308
Ayumi NiwaDepartment of Tumor Pathology, Gifu University Graduate School of Medicine, Gifu, 501-1194 Japan.
Fuminori HyodoDepartment of Radiology, Gifu University Graduate School of Medicine, Gifu, 501-1194 Japan.
Tomohiro KanayamaDepartment of Tumor Pathology, Gifu University Graduate School of Medicine, Gifu, 501-1194 Japan.
Mikiko MatsuoDepartment of Tumor Pathology, Gifu University Graduate School of Medicine, Gifu, 501-1194 Japan.
Yuko ImaizumiDepartment of Tumor Pathology, Gifu University Graduate School of Medicine, Gifu, 501-1194 Japan.
Takahiro KurodaDepartment of Tumor Pathology, Gifu University Graduate School of Medicine, Gifu, 501-1194 Japan.
Yuichiro HatanoDepartment of Tumor Pathology, Gifu University Graduate School of Medicine, Gifu, 501-1194 Japan.
Masafumi MiyaiDepartment of Neurosurgery, Ogaki Tokusyukai Hospital, Ogaki, Gifu 503-0015 Japan.
Yusuke EgashiraDepartment of Neurosurgery, Gifu University Graduate School of Medicine, Gifu, 501-1194 Japan.
Yukiko EnomotoDepartment of Neurosurgery, Gifu University Graduate School of Medicine, Gifu, 501-1194 Japan.
Noriyuki NakayamaDepartment of Neurosurgery, Gifu University Graduate School of Medicine, Gifu, 501-1194 Japan.
Shigeyuki SugieDepartment of Pathology, Asahi University Hospital, Gifu, 500-8523 Japan.
Kazu MatsumotoDepartment of Orthopaedic Surgery, Gifu University Graduate School of Medicine, Gifu, 501-1194 Japan.
Yu YamaguchiSanford Burnham Prebys Medical Discovery Institute, La Jolla, San Diego, CA USA.
Masayuki MatsuoDepartment of Radiology, Gifu University Graduate School of Medicine, Gifu, 501-1194 Japan.
Hideaki HaraMolecular Pharmacology, Department of Biofunctional Evaluation, Gifu Pharmaceutical University, Gifu, 501-1196 Japan.
Toru IwamaDepartment of Neurosurgery, Gifu University Graduate School of Medicine, Gifu, 501-1194 Japan.
Akira HaraDepartment of Tumor Pathology, Gifu University Graduate School of Medicine, Gifu, 501-1194 Japan.
Gifu University · JPAsahi University · JPGifu Pharmaceutical University · JPOgaki Municipal Hospital · JPSanford Burnham Prebys Medical Discovery Institute · US

Funding

Heparan Sulfate in Skeletal Development and DiseasesR01AR055670 · NIAMS · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI YAMAGUCHI, YU · 2008 to 2018
$4.9M
Japan Agency for Medical Research and Development JP18CM0106435H0001Japan Society for the Promotion of Science JP15K11289Japan Society for the Promotion of Science JP19K18385Japan Society for the Promotion of Science JP24590911NIAMS NIH HHS R01 AR055670
6 · The paper itself

Abstract

purposeHeparan sulfate (HS) is one of the factors that has been suggested to be associated with angiogenesis and invasion of glioblastoma (GBM), an aggressive and fast-growing brain tumor. However, it remains unclear how HS of endothelial cells is involved in angiogenesis in glioblastoma and its prognosis. Thus, we investigated the effect of endothelial cell HS on GBM development.

methodsWe generated endothelial cell-specific knockout of

resultsThe endothelial cell-specific

conclusionsHS reduction in the vascular endothelium of the brain suppressed GBM growth and neovascularization in mice. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12672-021-00444-3.

Indexed as

AngiogenesisFibroblast growth factor 2GlioblastomaHeparan sulfate

Identifiers

PMID34790962
PMCPMC8585801
OpenAlexW3213120056

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.